Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement

Laurence Klotz, MD, FRCSC1; Bobby Shayegan, MD, FRCSC2; Chantal Guillemette, PhD3; Loretta L. Collins, PhD4; Geoffrey Gotto, MD, MPH, FRCSC5; Dominique Guérette, PhD, CSPQ, FCACB6; Marie-Paule Jammal, MD, FRCSC7; Tom Pickles, MD, FRCPC8; Patrick O. Richard, MD, MSc, FRCSC9; Fred Saad, MD, FRCSC9

1Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON; 2McMaster University, Hamilton, ON; 3Université Laval and CHU de Québec-Université Laval, Quebec City, QC; 4Kaleidoscope Strategic, Toronto, ON; 5University of Calgary, Calgary, AB; 6Université de Montréal, Laval, QC; 7BC Cancer, Vancouver, BC; 8Centre Hospitalier Universitaire de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, QC; 9Centre Hospitalier de l’Université de Montréal, Montreal, QC; Canada

Cite as: Can Urol Assoc J 2018;12(2):30-7. http://dx.doi.org/10.5489/cuaj.5116

Published online December 19, 2017

Supplementary data available at cuaj.ca

Abstract

Testosterone suppression, achieved through orchiectomy or medically induced androgen-deprivation therapy (ADT), is a standard treatment for men with recurrent and metastatic prostate cancer. Current assay methods demonstrate the capacity for testosterone suppression to <0.7 nmol/l, and clinical data support improved outcomes from ADT when lower levels are achieved. Practical clinical guidelines are warranted to facilitate adoption of 0.7 nmol/l as the new standard castrate testosterone level.

A pan-Canadian group of experts, representing diverse clinical specialties, identified key clinical issues, searched and reviewed relevant literature, and developed consensus statements on testosterone suppression for the treatment of prostate cancer. The expert panel found that current evidence supports the clinical benefit of achieving low testosterone levels during ADT, and encourage adoption of ≤0.7 nmol/l as the new standard castrate testosterone level.

A steering committee of four clinical experts surveyed clinical issues among participants who represented multiple clinical specialties (academic/community urology, radiation oncology, and clinical biochemistry) and provided a pan-Canadian perspective. The steering committee conducted a topic-directed literature search, and developed proposed consensus statements that addressed clinical issues. All statements were graded by level of supporting evidence and level of consensus according to National Comprehensive Cancer Network (NCCN) consensus methodology (Table 1).14,15 Between September 5 and October 11, 2017, experts virtually reviewed and voted on proposed consensus statements. Statements not approved via ≥85% consensus were revised and confirmed at >85% in a second round of review and voting.

Introduction

Prostate cancer remains the most common cancer diagnosis in men in Canada and is still among the top three leading causes of cancer death.1 Men with early disease generally have a good prognosis; however, disease recurrence after initial treatment remains significant.2-5 Androgen-deprivation therapy (ADT) is the standard first-line treatment for men with recurrent or metastatic prostate cancer.6 The goal of ADT is suppression of testosterone, an androgenic hormone associated with growth and progression of prostate cancer.7 There is mounting evidence that suppression of patients’ testosterone levels below the historical castrate standard of 1.7 nmol/l (e.g., ≤0.7–1.1 nmol/l), is associated with improved treatment outcomes vs. patients with higher levels.8-13 Although data support a relationship between lower testosterone levels and clinical benefit, many questions remain on how to translate this knowledge to practice.13 This Canadian consensus summarizes evidence and provides guidance developed by a multidisciplinary panel of experts to assist practicing clinicians in implementing a lower castrate testosterone threshold during ADT for prostate cancer.
Table 1. NCCN consensus methodology\textsuperscript{14,15}

<table>
<thead>
<tr>
<th>Description</th>
<th>Level of consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category 1 – Based upon high-level evidence, there is uniform consensus that the intervention is appropriate</td>
<td>Uniform consensus: ≥85% agreement</td>
</tr>
<tr>
<td>Category 2A – Based upon lower-level evidence, there is uniform consensus that the intervention is appropriate</td>
<td>Uniform consensus: ≥85% agreement</td>
</tr>
<tr>
<td>Category 2B – Based upon lower-level evidence, there is consensus that the intervention is appropriate</td>
<td>Non-uniform consensus: 50–84% agreement</td>
</tr>
<tr>
<td>Category 3 – Based upon any level of evidence, there is major disagreement that the intervention is appropriate</td>
<td>No consensus: &lt;50% agreement</td>
</tr>
</tbody>
</table>

Consensus statements

1. Clinical benefit of low testosterone during ADT

Studies of the association of testosterone suppression level during ADT and outcomes of therapy have consistently demonstrated clinical benefit and importance of greater testosterone suppression during ADT.\textsuperscript{8,12,16} Prospective studies of ADT for the treatment of prostate cancer have assessed a range of testosterone level thresholds below the historical castrate level standard, including ≤0.7, ≤0.9, ≤1.0, or ≤1.1 nmol/l, and demonstrated that patients achieving these low levels had longer time to castration-resistant prostate cancer (CRPC) or death than their counterparts with respectively higher levels (Table 2).\textsuperscript{8,12} The largest prospective trial enrolled 626 patients with localized or locally advanced prostate cancer with treatment via orchietomy, or luteinizing hormone-releasing hormone (LHRH) agonist (LHRHa) therapy plus a non-steroidal anti-androgen for at least four weeks.\textsuperscript{8,16} Assessment of serum testosterone levels was completed every two months and results indicated that lower testosterone level was associated with longer time to CRPC. Analysis of testosterone levels during the first year of ADT demonstrated that time to CRPC was significantly improved for patients with nadir testosterone levels ≤0.7 nmol/l, compared with those with levels between >0.7 nmol/l and <1.1 nmol/l or ≥1.7 nmol/l (p=0.015). Median times to CRPC were 10.0, 7.21, and 3.62 years, respectively. Additionally, median testosterone level >0.7 nmol/l was associated with a higher risk of developing CRPC compared with lower levels (p=0.02; Table 2).\textsuperscript{8,16}

In retrospective analyses of ADT outcomes, including rates of testosterone breakthrough, progression-free survival (PFS), cause-specific survival (CSS), or overall survival (OS), relative to testosterone suppression level, four out of six studies demonstrated improved outcomes among patients with testosterone levels of ≤0.7 nmol/l or ≤1.1 nmol/l vs. respectively higher levels.\textsuperscript{17-20}

Of the thresholds examined, ranging from ≤0.7 to ≤1.1 nmol/l, the greatest number of studies supported a testosterone suppression threshold of 0.7 nmol/l. There was a clinical benefit associated with concentrations at or below this cutoff.\textsuperscript{8,9,12,16-18} These data suggest that 0.7 nmol/l is an appropriate target testosterone level during ADT.\textsuperscript{16} Based on the available evidence, we offer the following consensus statements.

CONSENSUS STATEMENT 1

In men receiving ADT for prostate cancer:

1a. There appears to be a clinical benefit associated with achieving a serum testosterone level of ≤0.7 nmol/l (Category 2A)

1b. Testosterone suppression to ≤0.7 nmol/l is a reasonable clinical goal (Category 2A)

Although current evidence supports adoption of a new castrate level threshold of ≤0.7 nmol/l during ADT, additional prospective studies are necessary to determine and validate the optimal threshold associated with the greatest therapeutic benefit.\textsuperscript{16}

2. Application

2a. Frequency of testosterone and prostate-specific antigen (PSA) testing

Given the benefit of achieving a target testosterone level of ≤0.7 nmol/l, testosterone assay timing is important. Current guidelines support the goal of achieving castrate testosterone levels within the first year of ADT.\textsuperscript{8,21,22} Although new dissolvable implants and gel-based depots permit more flexible dosing frequencies, physicians should consider monitoring testosterone every 3–6 months, or as appropriate, during the first year to ensure target levels are achieved\textsuperscript{8,21,22} Once the target threshold has been reached, lengthening the monitoring frequency as appropriate for a patient’s risk of relapse would be acceptable.

As a marker of testosterone signaling and disease control or potential progression, regular monitoring of PSA level is also recommended every 3–6 months, or as clinically appropriate.\textsuperscript{11,16,21,22}

CONSENSUS STATEMENT 2a

Prescribers of ADT should perform regular monitoring of testosterone and PSA levels throughout the first year of treatment (Category 2A)

2b. Accuracy of testing and collaboration with clinical labs

The first hormone assays were developed decades ago, and their limited sensitivity had a significant influence in setting the historical castrate testosterone level standard of 1.7 nmol/l.\textsuperscript{24-27} More recent technological advances in assay
Table 2. Prospective studies of androgen-deprivation therapy outcomes by testosterone level

<table>
<thead>
<tr>
<th>Study type/n/ setting</th>
<th>ADT regimen(s)</th>
<th>T level</th>
<th>Time to CRPC (months) HR (95% CI)</th>
<th>PFS (months) HR (95% CI)</th>
<th>OS (months) HR (95% CI) or range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klotz 2015² RCT, Multicentre 626 Recurrent</td>
<td>Orchiectomy or LHRH(a) plus non-steroidal anti-androgen for minimum of 4 weeks</td>
<td>≤0.7 nmol/l (NT year 1; n=489)</td>
<td>10.0a (yrs) (p=0.015b)</td>
<td>NR</td>
<td>Not reached⁴ (CSS; p=0.02³)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;0.7 to &lt;1.7 nmol/l (NT year 1; n=129)</td>
<td>7.21a (yrs) 1.62 (1.20–2.18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥1.7 nmol/l (NT year 1; n=8)</td>
<td>3.62a (yrs) 1.90 (0.98–4.70)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang 2016¹² Single-centre 206 Met</td>
<td>LHRH(a) every mo. or long-acting LHRH(a) every 3 mo. Bicalutamide 50 mg/day Secondary HT of LHRH(a) and flutamide 250 mg 3 times a day after bicalutamide withdrawal for 6 weeks</td>
<td>≤0.9 nmol/l (n=98)</td>
<td>19.1c (p=0.0004)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;0.9 nmol/l (n=108)</td>
<td>14.6c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bertaglia 2013⁹ Single-centre 153 L, LA, &amp; met</td>
<td>LHRH(a) (long-acting formulation) every 3 mo. Bicalutamide 50 mg daily during the first 4 weeks</td>
<td>&lt;0.7 nmol/l (n=25) vs. &gt;0.7 nmol/l (n=128)</td>
<td>NR</td>
<td>0.58 (0.30–1.15) (TTP; p=0.12)</td>
<td>0.19 (0.04–0.76) (p=0.020)⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≤1.0 nmol/l (n=56) vs. &gt;1.0 nmol/l (n=97)</td>
<td></td>
<td>0.76 (0.46–1.26) (TTP; p=0.30)</td>
<td>0.45 (0.22–0.94) (p=0.034)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;1.7 nmol/l (n=94) vs. ≥1.7 nmol/l (n=59)</td>
<td></td>
<td>0.84 (0.52–1.37) (TTP; p=0.51)</td>
<td>0.74 (0.42–1.33) (p=0.32)</td>
</tr>
<tr>
<td>Kawakami 2013¹¹ Single-centre 69 Met</td>
<td>LHRH(a) (goserelin, leuprolide, or buserelin)</td>
<td>≤0.7 nmol/l (n=56)</td>
<td>NR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;0.7 nmol/l (n=13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dason 2013¹⁰ Cohort series 32 L, LA, &amp; met</td>
<td>LHRH(a) (goserelin, leuprolide, or triptorelin), 3-month depots and a 1-month course of bicalutamide on ADT initiation OR LHRH antagonist (degarelix), 1-month depots</td>
<td>&lt;1.1 nmol/l (1 yr; n=28)</td>
<td>33.1⁴ (p&lt;0.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.1-1.7 nmol/l (1 yr; n=4)</td>
<td>12.5⁴</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other results:
- PSA minimum, maximum, median, and mean were all higher for the cohort of patients with levels of T >0.7 nmol/l.
- PSA correlated with total T (correlation 0.42; p=0.003).
- T levels >0.7 nmol/l were found in 17% (7/41), 19% (4/21), and 28% (2/7) of patients on goserelin, leuprolide, and buserelin, respectively.
- No statistical difference among the 3 LHRH agonists in proportion of patients not achieving optimal levels of T.

Other results:
- Patients with a 9-month absolute T measurement <1.1 nmol/l had increased time to CRPC (p=0.001, median: 33.1 months [<1.1 nmol/l] vs. 12.5 months [>1.1 nmol/l]).
- Patients with a 6-month absolute T <1.1 nmol/l had an increased time to CRPC, which was not statistically significant (p=0.085, median: 33.1 months [<1.1 nmol/l] vs. 14.6 months [>1.1 nmol/l]).
- Mean T level <0.7 nmol/l compared to 0.7 to 1.7 nmol/l at 6, 9, or 12 months did not significantly predict time to CRPC.

*Median; †adjusted for multiple test based on the Hochberg method (Hochberg et al. Biometrics 1988;75:800-2); °mean; ¯serum T level <0.7 nmol/l significantly associated with lower risk of death. ADT: androgen-deprivation therapy; CI: confidence interval; CRPC: castration-resistant prostate cancer; CSS: cause (cancer)-specific survival; HR: hazard ratio; HT: hormonal therapy; L: localized; LA: locally advanced; LHRH(a): luteinizing hormone-releasing hormone (agonist); Met: metastatic; mo: month(s); NR: not reported; NT: nadir testosterone; OS: overall survival; PFS: progression-free survival; PSA: prostate-specific antigen; RCT: randomized controlled trial; T: testosterone; TTP: time to progression; yr(s): year(s). Adapted from Klotz et al. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Can Urol Assoc J 2017;11:16-23. Copyright 2017 by CUA. Adapted with permission.
methodology include improved immunoassays (IA) and the development of mass spectrometry (MS), allowing greater sensitivity and accuracy of detection. IA has long been the standard method for testosterone measurement and is most commonly used; however, there are significant limitations in specificity and, therefore, accuracy of IAs, particularly at the new target testosterone threshold of ≤0.7 nmol/l (Fig. 1A). A recent study by Morote et al demonstrated the lack of reliability of IAs in the context of ADT for prostate cancer. This prospective study, enrolling 249 patients, compared two commercially available IAs and reported that the methods showed different behaviours, with modest correlation between them. One method showed only 24.9% of patients with levels below the threshold of 0.7 nmol/l, and the other indicated that over 77.5% of patients had testosterone levels below 0.7 nmol/l. These data suggest that IA methods could compromise the monitoring of castrate testosterone levels and, therefore, evaluation of ADT.

In contrast, several studies have demonstrated that the variability of results obtained with different MS-based assays is substantially less than those obtained by IA methods (especially at low testosterone concentrations), and confirmed that the threshold of sensitivity of MS is sufficient for monitoring testosterone in the context of ADT (Fig. 1B). As an example, an externally validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method was used to assess testosterone levels in men on ADT. A total of 34 men underwent surgical castration and 32 men received an LHRHa. Serum samples were collected and analyzed by LC-MS/MS ≥3 months from the date of surgery or initiation of medical ADT. Results showed that men on LHRHa had significantly lower testosterone levels (median 4.0 ng/dl [0.14 nmol/l], range <2.9–20.2 ng/dl [<0.1–0.7 ng/dl]) compared to those surgically castrated (median 9.2 ng/dl [0.32 nmol/l], range <2.9–28.8 ng/dl [<0.1 to 1.0 nmol/l]; p<0.001), demonstrating the ability of this method to accurately differentiate testosterone levels in the castrate range.

Use of LC-MS/MS is becoming more prevalent in clinical labs, while also accessible through outsourcing of sample analysis to validated LC-MS/MS reference laboratories. Average turnaround times for outsourced samples range from 7–10 days. LC-MS/MS should be considered the gold standard for testosterone assay at levels ≤0.7 nmol/l and sought out as a preferred method of testing over IA. Indeed, the American Endocrine Society recommends use of only MS for the measurement of testosterone at low levels. If regular use of LC-MS/MS for low level testosterone assay is either unavailable or not feasible through onsite analysis or outsourcing, IA methods validated against MS may be considered.

Fig. 1A. Limitations of immunoassays at low testosterone levels. Due to a lack of specificity, interference by serum or plasma components, particularly when testosterone levels are low (1, 2), may result in inaccurate measurements. Immunoassays tend to overestimate steroid levels at low concentrations (3).

**CONSENSUS STATEMENTS 2b-1 and 2b-2**

2b-1. For men with recurrent or metastatic prostate cancer receiving ADT:
- IA may not be sufficiently specific, sensitive, accurate, or reproducible in the detection of castrate level serum testosterone unless the method is externally validated against MS
- Validated LC-MS/MS methods are the gold standard for castrate level testosterone assays, with adequate specificity, sensitivity, and accuracy at low concentrations (≤0.7 nmol/l) (Category 2A)

2b-2. Clinicians treating men with recurrent or metastatic prostate cancer receiving ADT:
- Should consider encouraging access to validated testosterone assays, preferably by LC-MS/MS, either at their centre or through collaboration with other centres
- Should consider ways to communicate the need for testosterone assay in the castrate range and consider providing additional notation with the requisition to promote reliable and accurate testosterone assessment at low levels (Category 2A)
An important aspect in establishing assays for testosterone measurement in local clinical laboratories is participation in accuracy-based external quality assessment (EQA) and standardization programs for both MS and IA. EQA programs ensure assay reliability over time and allow standardization of testosterone measures across laboratories (see supplementary data for details on measures of accuracy; available at cuaj.ca).41,43-48 These assessments are essential to ensuring ongoing reliability of results at low testosterone concentrations.

Given the potential variability in testing methods available at clinical labs, clinicians should clearly express their assay needs by requesting low/castrate testosterone levels for patients on ADT. They may also consider adding notation to the requisition form or including an accompanying note or additional material (e.g., information presented in supplementary data; available at cuaj.ca) to reinforce the need for use of an assay method that is accurate at low testosterone levels.

3. Management

Clinical management strategies are necessary to address cases in which testosterone and/or PSA thresholds are not achieved. Testosterone levels during ADT reflect the efficacy of treatment, while the serum PSA concentrations are a reflection of disease control. Preferably, both testosterone and PSA levels remain low (≤0.7 nmol/l and ≤2 ng/ml, respectively), but if either begins to rise, reassessment and a change in therapeutic strategy may be warranted. There are two general scenarios defined by testosterone level (i.e., inadequate vs. adequate testosterone suppression) that can be used to guide treatment strategy, with further differentiation according to relative PSA levels (Figs. 2, 3).

3a. Inadequately suppressed testosterone

The first scenario applies to patients receiving ADT and demonstrating consistently inadequate testosterone suppression, as assessed via testosterone measurements taken during continuous ADT or the on-therapy intervals of intermittent ADT within the first year.8,16 These patients may have either stable or rising PSA levels. For those with stable PSA (non-metastatic or metastatic), a testosterone level above 0.7 nmol/l may indicate treatment failure and alternate medical or surgical treatments should be considered (Fig. 2).8,16 For those with rising PSA, inadequate testosterone suppression may also indicate treatment failure. For non-metastatic or metastatic disease, alternate medical or surgical treatments should be considered.16 In either case, combined androgen blockade with a non-steroidal anti-androgen may provide protection against the effects of failure to suppress serum testosterone below 0.7 nmol/l;18 however, for those with metastatic disease, testosterone level <1.7 nmol/l and PSA >2 ng/ml, treatment for CRPC following Canadian Urological Association-Canadian Urologic Oncology Group (CUA-CUOG) guidelines should be implemented.49

CONSENSUS STATEMENT 3a
For men with recurrent or metastatic prostate cancer receiving ADT, a testosterone level consistently above the target threshold of 0.7 nmol/l may indicate treatment failure and alternate medical or surgical therapy should be considered (Category 2A).

3b. Adequately suppressed testosterone

The second scenario applies to patients receiving ADT with adequately suppressed testosterone. In this case, stable PSA indicates effective disease control and patients should continue their current ADT (Fig. 3). Rising PSA in the context of suppressed testosterone may indicate CRPC.16 For non-metastatic patients, addition or withdrawal of an anti-androgen may be considered, while treatment for the management of CRPC49 is recommended for patients with metastatic disease. For patients receiving intermittent ADT, rising PSA levels during the off-treatment interval occur normally, prompting re-initiation of therapy, usually when the PSA reaches a level of 10–20 ng/ml.16

The current recommendations for management of recurrent or metastatic prostate cancer are based on available evidence and expert consensus regarding standards of cur-
Consensus: Testosterone suppression for advanced prostate cancer

4. Knowledge translation

Identification, clinical assessment, and documentation of the link between achieving lower testosterone levels during ADT and improved outcomes for prostate cancer patients are essential first steps in improving patient care; however, distribution of knowledge and translation to clinical application are necessary to ensure a real clinical impact. A recent survey of Canadian clinicians treating prostate cancer suggests a fundamental knowledge gap regarding the practical steps needed to ensure maximal testosterone suppression during ADT. Among surveyed Canadian urologists, uro-oncologists, and radiation oncologists treating prostate cancer, including community urologists, approximately one-third were unaware of the lower limit of detection of the castrate testosterone assays used. Approximately 40% were monitoring testosterone regularly (e.g., every 3–6 months, or prior to each LHRHa injection), and the majority were unaware of the testosterone assay method used in their centre/laboratory.

There is a need for increased awareness regarding the importance and implications of testosterone suppression during ADT, as well as a baseline level of technical knowledge for proper selection and interpretation of testosterone assay data to guide assay selection and ensure detectability at or below 0.7 nmol/l.

Summary and conclusions

Optimal care for men receiving ADT for prostate cancer includes the testosterone suppression goal of ≤0.7 nmol/l, regular monitoring of testosterone and PSA levels, and reassessment of therapeutic strategy if: 1) serum testosterone is not suppressed; or 2) PSA rises regardless of adequate testosterone suppression. We encourage clinicians to be aware of the assays used to assess testosterone level in samples from patients on ADT, and to ensure that the laboratories selected provide LC-MS/MS analysis calibrated for low testosterone levels, whether it is achieved in-house or via outsourcing.

Competing interests: Dr. Klotz has received honoraria from Abbvie, Amgen, Astellas, Aventis, Janssen, and Sanofi; and research funding from Ferring. Dr. Shayegan has received grants or honoraria from Abbvie, Astellas, Janssen, and Sanofi; and participated in clinical trials sponsored by Astellas and Janssen. Ms. Collins has received compensation from Kaleidoscope Strategic, an oncology publications firm. Dr. Gotto has served as a consultant.
or advisor for, and received grants or honoraria from Amgen, Astellas, Bayer, Bristol Myers Squibb, Janssen, Pfizer, and Roche; and has participated in clinical trials sponsored by Amgen Pharmaceuticals, Bayer, Janssen, Myovant Sciences, and Pfizer. Dr. Jamal has served as a consultant for Astellas, Janssen, Pfizer, and Sanofi; holds ownership interest in GSK; has received honoraria from Astellas and Pfizer; has received research funding from Abbvie, Astresas, and Asto Zeneca; and has received other remuneration from Sanofi. Dr. Pickles has served on an advisory board and as a consultant for Abbvie, Ferring, and Sanofi. Dr. Richard has served on an advisory board for Bristol Myers Squibb and Sanofi; and has received honoraria or grants from, Abbvie, Astellas, and Janssen. Dr. Saad has served as a consultant for Abbvie, Sanofi, and Taekeda; received honoraria from Abbvie, Sanofi, and Taekeda; and received research funding from Sanofi and Taekeda. The remaining authors report no competing personal or financial interests.

Acknowledgment: The authors thank Deanna McLeod of Kaleidoscope Strategic for research, editorial, and administrative support in preparing the consensus statement.

Funding: Publication support services were funded in an independent fashion by Sanofi Canada. The opinions presented in the paper represent those of the authors and not the sponsor; none of the clinical authors were paid for writing this article. The sponsor did not contribute to the design or development of the article and did not see the manuscript prior to submission.

This paper has been peer-reviewed.

References


Correspondence: Dr. Laurence Klotz, University of Toronto, Toronto, ON, Canada; laurence.klotz@sunnybrook.ca

The Juravinski Cancer Centre Uro-Oncology Forum 2018

The JCC Uro-Oncology Forum will bring together experts from the Juravinski Cancer Centre and the Walker Family Cancer Centre and is set to target community urologists, medical oncologists and radiation oncologists in Ontario. Scientific sessions will focus on bladder, kidney and prostate cancers along with a research update on clinical trials.

The Juravinski Cancer Centre
Uro-Oncology Forum 2018

April 13-14, 2018
Pillar and Post Inn
Niagara-on-the-Lake, ON

Friday, April 13, 2018
8:00 - 15:00 Scientific Sessions
18:00 - 21:00 Welcome Dinner

Saturday, April 14, 2018
8:00 - 15:00 Scientific Sessions